SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Ernest Shackleton

PatientErnest Shackleton
Date of birth1979-02-15
IdentifiersMRN HR-EX001-SYN; SSN (made up) 000-01-7763
Document date2026-07-21
AuthorCormac Ellingsworth-Daly, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Ten-week review, three weeks after a coronary stent. [S]

History of Present Illness

Mr. Shackleton returns three weeks after coronary angiography, at which a drug-eluting stent was placed in the proximal left anterior descending artery through the right wrist, with no complications; he went home the same day. He has had no chest tightness since, even on the stairs with a load, and has not needed nitroglycerin. The wrist bruise has faded. He takes aspirin and clopidogrel every day and has had no bleeding beyond easy bruising on his forearms. He has not smoked for nine weeks. He drinks on four or five evenings a week, usually two drinks, sometimes three at dinners. He is impatient to get fit for the voyage. [S]

ElementDetail
AnginaNone since the stent
Access siteRight wrist healed
AntiplateletsAspirin and clopidogrel daily; minor bruising only
TobaccoNot smoked for nine weeks
AlcoholTwo, sometimes three, drinks on four or five evenings a week

Review of Systems

SystemResultFinding
CardiovascularNegativeNo chest pain, palpitations, or swelling
HematologicPositiveEasy bruising on the forearms; no nosebleeds, black stools, or blood in the urine
MusculoskeletalNegativeNo muscle aches

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release tablet, one tablet by mouth dailyonce dailyOral route2026-05-12activeS
Atorvastatin 80 mg tablet, one tablet by mouth dailyonce dailyOral route2026-05-12activeS
Metoprolol succinate extended-release 50 mg tablet, one tablet by mouth dailyonce dailyOral route2026-05-12 to 2026-05-26stoppedS
Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue for chest pain, repeat every 5 minutes up to 3 dosesas needed for chest pain, up to 3 dosesSublingual route2026-05-12activeS
Varenicline 1 mg tablet, one tablet by mouth twice a day after a one-week starter titrationtwice a day after titrationOral route2026-05-12activeS
Metoprolol succinate extended-release 100 mg tablet, one tablet by mouth dailyonce dailyOral route2026-05-26activeS
Clopidogrel 75 mg tablet, one tablet by mouth daily for six months after the stent (600 mg loading dose before the procedure)once daily for six monthsOral route2026-07-01activeS
Ezetimibe 10 mg tablet, one tablet by mouth dailyonce dailyOral route2026-07-21activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-21Body height175cmS
2026-07-21Body weight84.4kgS
2026-07-21Body mass index (BMI) [Ratio]27.6kg/m2S
2026-07-21Systolic blood pressure124mm[Hg]S
2026-07-21Diastolic blood pressure78mm[Hg]S
2026-07-21Heart rate58/minS
2026-07-21Respiratory rate14/minS
2026-07-21Body temperature36.7CelS
2026-07-21Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-21Cholesterol [Mass/volume] in Serum or Plasma128mg/dL<=199 mg/dLNormalS
2026-07-21Cholesterol in HDL [Mass/volume] in Serum or Plasma44mg/dL>=40 mg/dLNormalS
2026-07-21Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation62mg/dLBelow 100 for the general population; below 55 is his treatment targetNormalS
2026-07-21Triglyceride [Mass/volume] in Serum or Plasma110mg/dL<=149 mg/dLNormalS
2026-07-21Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-52 U/LNormalS
2026-07-21Total score [AUDIT-C]4{score}S

Physical Exam

Vital signs recorded on 2026-07-21; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 124/78, pulse 58, weight 84.4 kg
CardiovascularRegular rhythm; no murmur; right radial pulse normal; access site healed
SkinTwo small bruises on the forearms

Problems

ProblemClinical statusVerificationCodeProvenance
Chest tightness and breathlessness on exertion for about three months, brought on by stairs, carrying loads, and walking fast in cold wind and relieved within minutes by rest, never at rest; resting ECG normal; cause not yet established at intake; coronary CT angiography and cardiology consultation requestedresolvedconfirmed R07.89S — Synthetic presenting problem anchored to his documented exertional breathlessness; superseded by the diagnosis at the cardiology consultation.
Nicotine dependence, cigarettes: about 25 a day since 16 (about 39 pack-years)activeconfirmed F17.210S — Synthetic modern coding anchored to his documented heavy smoking.
Chronic coronary disease with stable exertional angina: 80% stenosis of the proximal left anterior descending artery with CT-FFR 0.70, mild right coronary artery disease, coronary calcium score 210, and normal left ventricular function; synthetic modern episode linked to his documented exertional illnesses and the coronary atheroma recorded at his deathactiveconfirmed I25.118S — Synthetic modern diagnosis made at the cardiology consultation; Macklin's coronary diagnosis is recorded in CLM-0009 and the alternative theories as R.
Hyperlipidemia: LDL cholesterol 168 mg/dL and HDL 38 mg/dL at intakeactiveconfirmed E78.5S — Synthetic modern risk factor; no historical measurement exists.
Prediabetes: HbA1c 5.9% at intakeactiveconfirmed R73.03S — Synthetic modern risk factor; no historical measurement exists.
Drug-eluting stent in the proximal left anterior descending artery, placed for angina that persisted on medical therapy; dual antiplatelet therapy for six monthsactiveconfirmed Z95.5S — Synthetic status after the modern procedure.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure (target below 130/80 mmHg)Every visitCompleted today124/78 mmHg, at target
ExaminationWeight, BMI, and physical activityEvery visitCompleted today84.4 kg; walking daily
ExaminationAngina frequency and Canadian Cardiovascular Society class, nitroglycerin useEvery visitCompleted todayNo angina since the stent; no nitroglycerin
Medication safetyDual antiplatelet therapy: adherence and bleedingEvery visit during dual therapyCompleted todayBoth taken daily; minor bruising only; no NSAIDs
Medication safetyAdherence review: aspirin (or dual antiplatelet therapy), high-intensity statin, beta-blocker for anginaEvery visitCompleted todayAtorvastatin, metoprolol, and both antiplatelets taken daily
LaboratoryLipid panel4 to 12 weeks after starting or changing lipid therapy, then every 3 to 12 monthsCompleted todayLDL 62 mg/dL (63% reduction), above the target below 55; ezetimibe added
LaboratoryALT on high-intensity statinBaseline, then only with symptomsCompleted today31 U/L; drawn with the lipid panel
ImagingStress imaging, coronary CT angiography, echocardiography, or invasive angiographyOnly for new or worsening symptoms or a change in function despite optimized therapy; no routine surveillanceNot indicatedAsymptomatic after the stent; no surveillance imaging
Self-managementTobacco use and cessation support (varenicline with counseling)Every visitCompleted todayAbstinent for nine weeks
SurveyAlcohol use (AUDIT-C) and brief interventionEach visit until within limitsCompleted todayAUDIT-C 4, at the threshold; brief intervention repeated
ReferralCardiac rehabilitation referralAt diagnosis of stable angina, and after PCIReferredReferred today; first session next week. Protocol deviation: the referral was due at the diagnosis of stable angina at the consultation and was deferred for eight weeks while revascularization was decided. No harm is evident: he had no cardiac events and is angina-free. Corrective action: refer at diagnosis in future, whatever revascularization plan is pending
LaboratoryHbA1c for prediabetesEvery 3 to 6 months while lifestyle change is under way, then yearlyDueAt the pre-departure visit

Goal progress:

Guideline basis: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (Virani SS, et al. Circulation 2023;148(9):e9-e119) (2023); 2024 ESC Guidelines for the management of chronic coronary syndromes (Vrints C, et al. Eur Heart J 2024;45(36):3415-3537) (2024); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018)

Follow-up: Preventive visit in three weeks. Pre-departure review in seven weeks with an exercise test, lipids, and HbA1c. Next scheduled visit 2026-08-11: periodic adult preventive visit. [S]